You are here

Immunogenicity and Safety Study of a Third Vaccination With FSME-IMMUN 0.5 mL in Subjects Previously Vaccinated According to a Rapid Immunization Schedule (Follow-up to Study 225)

Last updated on May 11, 2018

FOR MORE INFORMATION
Study Location
SGS Biopharma Research Unit Stuivenberg
Antwerp, , 2060 Belgium
Contact
1-800-718-1021
Eligibility criteria
Condition
The disease, disorder, syndrome, illness, or injury that is being studied.
Tick-borne Encephalitis
Sex
Females and Males
Age
Pediatric Trials: 0-17 Years
Adult Trials: 18+ Years
17-66 years
Inclusion criteria
The factors, or reasons, that allow a person to participate in a clinical study.
Show details

- Male and female subjects who:

- received 2 vaccinations with FSME-IMMUN 0.5 ml during Study 225

- understand the nature of the study, agree to its provisions and provide written
informed consent

- are clinically healthy (i.e. the physician would have no reservation vaccinating with
FSME-IMMUN 0.5 ml outside the scope of the clinical trial)

- have a negative pregnancy test result at the first medical examination (if female and
capable of bearing children)

- agree to employ adequate birth control measures for the duration of the study (if
female and capable of bearing children)

- agree to keep a Subject Diary

Exclusion criteria
The factors, or reasons, that prevent a person from participating in a clinical study.
Show details

Subjects who:

- have already been administered a third TBE vaccination elsewhere since receiving two
vaccinations in Study 225

- have a history of infection with, or vaccination against, other flaviviruses since
participation in Study 225 (e.g. yellow fever, dengue fever, japanese B encephalitis)

- have had an allergic reaction to one of the components of the vaccine since
participation in Study 225

- suffer from a disease (e.g. autoimmune disease, immunodeficiency) or are undergoing a
form of treatment (e.g., systemic corticosteroids) that can be expected to influence
immunological functions

- have a known or suspected problem with drug or alcohol abuse (>4 liters wine/week or
equivalent doses of other alcoholic beverages)

- have donated blood or plasma within 30 days of study entry

- have received a blood transfusion or immunoglobulins within 30 days of study entry

- are known to be HIV positive (an HIV test is not required specifically for this study)

- are simultaneously participating in another clinical trial including administration of
an investigational product

- have participated in any other clinical study within 6 weeks prior to study start

- have participated in another Baxter vaccine study in the past 6 months (with the
exception of follow-up studies)

- For female subjects: pregnancy or lactation

NCT00163540
Pfizer
Completed
Immunogenicity and Safety Study of a Third Vaccination With FSME-IMMUN 0.5 mL in Subjects Previously Vaccinated According to a Rapid Immunization Schedule (Follow-up to Study 225)

NEED INFO?

Questions about a trial? Call or email to reach a Pfizer Clinical Trial Contact Center

Pfizer Clinical Trials Contact Center

1-800-718-1021

[email protected]

call now

Try a new search

Search for Clinical Trials by condition, keyword or trial number. Share your location or enter your zip code, city, or country to find studies near you.

Similar Trials

Tick-borne Encephalitis
NCT00161850
All Genders
1+
Years
Multiple Sites
Tick-borne Encephalitis
NCT00161889
All Genders
6+
Years
Multiple Sites
Tick-Borne Encephalitis
NCT00161967
All Genders
3+
Years
Multiple Sites
Immunogenicity and Safety Study of a Third Vaccination With FSME-IMMUN 0.5 mL in Subjects Previously Vaccinated According to a Rapid Immunization Schedule (Follow-up to Study 225)
Open-Label, Follow-up, Phase IV Clinical Study to Evaluate the Immunogenicity and Safety of a Third Vaccination With FSME-IMMUN 0.5 mL in Subjects Previously Vaccinated Using a Rapid Immunization Schedule (Follow-up to Study 225)
The objective of this study is to investigate the immunogenicity and safety of a third vaccination with FSME-IMMUN 0.5 ml given approximately 12 months after the second vaccination in Study 225. In Study 225, two vaccinations were given using a rapid immunization schedule 12 ± 2 days apart.
Not Provided
Interventional
Phase 4
Allocation: Non-Randomized
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Prevention
Encephalitis, Tick-borne
Biological: Formaldehyde inactivated, sucrose gradient purified TBE virus antigen, strain Neudörfl
Not Provided
Orlinger KK, Hofmeister Y, Fritz R, Holzer GW, Falkner FG, Unger B, Loew-Baselli A, Poellabauer EM, Ehrlich HJ, Barrett PN, Kreil TR. A tick-borne encephalitis virus vaccine based on the European prototype strain induces broadly reactive cross-neutralizing antibodies in humans. J Infect Dis. 2011 Jun 1;203(11):1556-64. doi: 10.1093/infdis/jir122.


*   Includes publications given by the data provider as well as publications
identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Completed
Not Provided
June 2005
Not Provided

Inclusion Criteria:

  • Male and female subjects who:
  • received 2 vaccinations with FSME-IMMUN 0.5 ml during Study 225
  • understand the nature of the study, agree to its provisions and provide written informed consent
  • are clinically healthy (i.e. the physician would have no reservation vaccinating with FSME-IMMUN 0.5 ml outside the scope of the clinical trial)
  • have a negative pregnancy test result at the first medical examination (if female and capable of bearing children)
  • agree to employ adequate birth control measures for the duration of the study (if female and capable of bearing children)
  • agree to keep a Subject Diary

Exclusion Criteria:

Subjects who:

  • have already been administered a third TBE vaccination elsewhere since receiving two vaccinations in Study 225
  • have a history of infection with, or vaccination against, other flaviviruses since participation in Study 225 (e.g. yellow fever, dengue fever, japanese B encephalitis)
  • have had an allergic reaction to one of the components of the vaccine since participation in Study 225
  • suffer from a disease (e.g. autoimmune disease, immunodeficiency) or are undergoing a form of treatment (e.g., systemic corticosteroids) that can be expected to influence immunological functions
  • have a known or suspected problem with drug or alcohol abuse (>4 liters wine/week or equivalent doses of other alcoholic beverages)
  • have donated blood or plasma within 30 days of study entry
  • have received a blood transfusion or immunoglobulins within 30 days of study entry
  • are known to be HIV positive (an HIV test is not required specifically for this study)
  • are simultaneously participating in another clinical trial including administration of an investigational product
  • have participated in any other clinical study within 6 weeks prior to study start
  • have participated in another Baxter vaccine study in the past 6 months (with the exception of follow-up studies)
  • For female subjects: pregnancy or lactation
Sexes Eligible for Study: All
17 Years to 66 Years   (Child, Adult, Senior)
Yes
Contact information is only displayed when the study is recruiting subjects
Belgium
 
 
NCT00163540
690501
Not Provided
Not Provided
Not Provided
Not Provided
Pfizer
Not Provided
Principal Investigator: Baxter BioScience Investigator, MD Baxter BioScience
Pfizer
May 2015

ICMJE     Data element required by the

International Committee of Medical Journal Editors
and the
World Health Organization ICTRP

FOR MORE INFORMATION

Contact a representative by phone, email, or visiting thte study website. To get updates and notications about this trail, sign up using the form below.

BY PHONE

Pfizer Clinical Trials Contact Center

1-800-718-1021

BY EMAIL

Contact

[email protected]



Call Now